The terms, per the grant. On April 30, 2024, ModernaTX was issued US11969506B2, "Lipid nanoparticle formulation." The CPC tags — A61K 9/5123 (lipid-particle preparations), A61K 31/7088 (nucleic-acid actives), A61K 48/0033 (gene therapy), C12N 15/113 — describe the delivery formulation that encapsulates and protects mRNA payloads.
Why LNP IP is the platform: free mRNA is fragile and not readily delivered into cells; the lipid nanoparticle is what makes mRNA medicine possible. Formulation IP — the specific lipids and ratios — is therefore the reusable core that every mRNA program depends on, which makes it the asset behind platform licenses and collaboration upfronts.
The structure point: an LNP-formulation deal behaves like a platform license — the royalty base grows with each mRNA program that uses the formulation, partly independent of any single program's clinical fate. For a model, that is the diversified, compounding value at the heart of the modality.
What the grant does not promise: a clinical result for any program, an approval, or exclusivity over all delivery chemistries. It is an exclusivity claim on a specific formulation, within a field where multiple LNP and delivery approaches compete and where some foundational lipid IP is contested.
The takeaway: when valuing an mRNA platform deal, the LNP-formulation grants are the load-bearing assets. Moderna's April 2024 formulation grant is a dated, concrete brick in the delivery platform that mRNA economics rest on.